Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

Correlation Between Severity of Oral Mucositis and Both Overall and Gut Acute GvHD After High Intensity Conditioning Hematopoietic Stem Cell Transplantation.

Maria Elvira Correa, DDS, Mark M Schubert, DDS, MSD, Barry Storer, PhD, Paul J. Martin, MD, Mary E.D. Flowers, MD

Blood (2012) 120 (21): 3057.

https://doi.org/10.1182/blood.V120.21.3057.3057

Published: 2012

Journal Articles

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Merav Bar, MD, Barry Storer, PhD, Benedetto Bruno, MD, Parameswaran Hari, MBBS, MD, MRCP, Thomas Chauncey, MD, PhD, Yoshihiro Inamoto, MD, PhD, Paul J. Martin, MD, Rainer Storb, MD, David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Mary E.D. Flowers, MD

Blood (2012) 120 (21): 354.

https://doi.org/10.1182/blood.V120.21.354.354

Published: 2012

Journal Articles

Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center

Zandra K. Klippel, MD, Barry Storer, PhD, William I. Bensinger, MD, Leona Holmberg, MD, PhD, Pamela S Becker, MD, PhD, Damian J. Green, MD, Nicholas Burwick, MD, Edward N. Libby, III, MD

Blood (2012) 120 (21): 2016.

https://doi.org/10.1182/blood.V120.21.2016.2016

Published: 2012

Journal Articles

Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Boglarka Gyurkocza, M.D., Jonathan Gutman, MD, Eneida R. Nemecek, MD, Eileen Sickle, RN, Merav Bar, MD, Joachim Baumgart, PhD, Colleen Delaney, MD, MSc, Barry Storer, PhD, Frederick R. Appelbaum, MD, H. Joachim Deeg, MD

Blood (2012) 120 (21): 963.

https://doi.org/10.1182/blood.V120.21.963.963

Published: 2012

Journal Articles

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

Mohamed L. Sorror, MD, MSc, Brent R. Logan, PhD, Xiaochun Zhu, MS, J. Douglas Rizzo, MD, Kenneth R. Cooke, MD, Philip L. McCarthy, Jr., MD, Vincent T Ho, MD, Barry Storer, PhD, Marcelo C Pasquini, MD, MS

Blood (2012) 120 (21): 733.

https://doi.org/10.1182/blood.V120.21.733.733

Published: 2012

Journal Articles

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Frederick L Locke, MD, Joseph Pidala, MD, MS, Barry Storer, PhD, Paul J. Martin, MD, Michael A Pulsipher, MD, Thomas Chauncey, MD, PhD, Niels Jacobsen, MD, DMSC, Nikolaus Kroeger, MD, Irwin Walker, MBBS, Mary C Territo, Susan Light, MD, Ginna G Laport, MD, Auayporn Nademanee, MD, Raymond Powles, MD, Armand Keating, MD, Gerard Socie, MD, Claudio Anasetti, MD

Blood (2012) 120 (21): 4195.

https://doi.org/10.1182/blood.V120.21.4195.4195

Published: 2012

Journal Articles

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

Boglarka Gyurkocza, M.D., Rainer Storb, MD, Thomas Chauncey, MD, PhD, David G. Maloney, MD, PhD, Barry Storer, PhD, Brenda M. Sandmaier, MD

Blood (2012) 120 (21): 4207.

https://doi.org/10.1182/blood.V120.21.4207.4207

Published: 2012

Journal Articles

Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium

Yoshihiro Inamoto, MD, Corey S. Cutler, MD, MPH, FRCPC, Xiaoyu Chai, MS, Mukta Arora, MD, Paul J. Martin, MD, Joseph Pidala, MD, MS, Jeanne Palmer, MD, Steven Z. Pavletic, MD, Madan H. Jagasia, MD, David Jacobsohn, MD, Paul A. Carpenter, MD, Mary E.D. Flowers, MD, Nandita Khera, MD, Georgia B. Vogelsang, MD, Daniel J. Weisdorf, MD, Barry Storer, PhD, Stephanie J. Lee, MD, MPH

Blood (2011) 118 (21): 1988.

https://doi.org/10.1182/blood.V118.21.1988.1988

Published: 2011

Journal Articles

Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes

Fabiana Ostronoff, MD, Barry Storer, PhD, Rainer Storb, MD, Smita Bhatia, MD, MPH, Richard T. Maziarz, MD, Michael A. Pulsipher, MD, Michael T. Maris, MD, H. Joachim Deeg, M.D., Paul J. Martin, MD, Frederick R. Appelbaum, M.D., David G. Maloney, MD, PhD, Brenda M. Sandmaier, MD, Mohamed L. Sorror, MD, MSc

Blood (2011) 118 (21): 665.

https://doi.org/10.1182/blood.V118.21.665.665

Published: 2011

Journal Articles

Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Rainer Storb, MD, Brenda M. Sandmaier, MD, Smita Bhatia, MD, MPH, Richard T. Maziarz, MD, Michael A. Pulsipher, MD, Michael T. Maris, MD, H. Joachim Deeg, M.D., Frederick R. Appelbaum, MD, David G. Maloney, MD, PhD, Paul J Martin, MD, Barry Storer, PhD

Blood (2011) 118 (21): 326.

https://doi.org/10.1182/blood.V118.21.326.326

Published: 2011

Journal Articles

Incidence, Risk Factors and Outcomes of Sclerotic Chronic Graft-Versus-Host Disease (GVHD) Phenotype After Allogeneic Hematopoietic Cell Transplantation

Yoshihiro Inamoto, MD, Barry Storer, PhD, Effie W. Petersdorf, MD, Paul A. Carpenter, MD, Stephanie J. Lee, MD, MPH, Lee Nelson, MD, Brenda M. Sandmaier, MD, Paul J. Martin, MD, Mary E.D. Flowers, MD

Blood (2011) 118 (21): 322.

https://doi.org/10.1182/blood.V118.21.322.322

Published: 2011

Journal Articles

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Pamela S Becker, MD, PhD, Bruno C. Medeiros, MD, Frederick R. Appelbaum, MD, Bart Lee Scott, MD, Paul C. Hendrie, MD, PhD, Barry Storer, PhD, Sherry Pierce, RN, BS, Stephen H. Petersdorf, MD, Elihu H. Estey, MD

Blood (2011) 118 (21): 3617.

https://doi.org/10.1182/blood.V118.21.3617.3617

Published: 2011

Journal Articles

Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers

Brian Kornblit, MD, PhD, Billanna Hwang, Barry Storer, PhD, Monica S Thakar, MD, Erlinda B Santos, Richard A. Nash, MD, Brenda M. Sandmaier, MD

Blood (2011) 118 (21): 1891.

https://doi.org/10.1182/blood.V118.21.1891.1891

Published: 2011

Journal Articles

Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response

Jeanne Palmer, MD, Stephanie J. Lee, MD, MPH, Xiaoyu Chai, MS, Barry Storer, PhD, Joseph Pidala, MD, MS, Corey S. Cutler, MD, MPH, FRCPC, Mukta Arora, MD, Mary E.D. Flowers, MD, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Yoshihiro Inamoto, MD, Madan Jagasia, MD, MS, Chen George, MD, Paul J. Martin, MD

Blood (2011) 118 (21): 1978.

https://doi.org/10.1182/blood.V118.21.1978.1978

Published: 2011

Journal Articles

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Marco Mielcarek, MD, Barry Storer, PhD, Paul J. Martin, MD, Robert S Negrin, MD, Stephen J. Forman, MD, Mary E.D. Flowers, MD, Yoshihiro Inamoto, MD, Thomas Chauncey, MD, PhD, Rainer Storb, MD, Frederick R. Appelbaum, MD, William I Bensinger, MD

Blood (2011) 118 (21): 319.

https://doi.org/10.1182/blood.V118.21.319.319

Published: 2011

Journal Articles

Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes

Mohamed L. Sorror, MD, MSc, Fabiana Ostronoff, MD, Rainer Storb, MD, Smita Bhatia, MD, MPH, Richard T. Maziarz, MD, Michael A. Pulsipher, MD, Michael T. Maris, MD, H. Joachim Deeg, M.D., Paul J Martin, MD, Frederick R. Appelbaum, MD, David G. Maloney, MD, PhD, Brenda M Sandmaier, MD, Barry Storer, PhD

Blood (2011) 118 (21): 145.

https://doi.org/10.1182/blood.V118.21.145.145

Published: 2011

Journal Articles

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M. Sandmaier, MD, Leanthe Braunert, MD, Ginna G. Laport, MD, Thomas Chauncey, MD, Christopher Bredeson, Richard T Maziarz, MD, Michael A. Pulsipher, MD, Edward Agura, MD, Michael T. Maris, MD, Lars Vindelov, MD, Firoozeh Sahebi, M.D., Peter McSweeney, Benedetto Bruno, MD, Amelia Langston, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2364.

https://doi.org/10.1182/blood.V116.21.2364.2364

Published: 2010

Journal Articles

Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)

Mohamed L. Sorror, MD, MSc, Barry Storer, PhD, Brenda M Sandmaier, MD, Thomas Chauncey, MD, Michael T. Maris, MD, Rainer F. Storb, MD, David G. Maloney

Blood (2010) 116 (21): 2365.

https://doi.org/10.1182/blood.V116.21.2365.2365

Published: 2010

Journal Articles

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Sally Arai, MD, Madan Jagasia, MD, MS, Mukta Arora, MD, David Miklos, MD, PhD, Xiaoyu Chai, MS, Barry Storer, PhD, Paul J. Martin, Corey Cutler, MD, MPH, FRCPC, Daniel J. Weisdorf, MD, Joseph Pidala, Jeanne Palmer, MD, Mary Flowers, MD, David Jacobsohn, MD, Paul A. Carpenter, Steven Z. Pavletic, MD, Georgia B. Vogelsang, MD, Stephanie J. Lee

Blood (2010) 116 (21): 220.

https://doi.org/10.1182/blood.V116.21.220.220

Published: 2010

Journal Articles

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

Jennifer Vaughn, MD, MSPH, Barry Storer, PhD, Marco Mielcarek, MD, Edus H. Warren, III, MD, PhD, Paul J. Martin, MD, Brenda M. Sandmaier, MD, Elihu H. Estey, MD, Rainer Storb, MD, H. Joachim Deeg, MD, Bart Lee Scott, MD

Blood (2010) 116 (21): 1288.

https://doi.org/10.1182/blood.V116.21.1288.1288

Published: 2010

NARROW

Correlation Between Severity of Oral Mucositis and Both Overall and Gut Acute GvHD After High Intensity Conditioning Hematopoietic Stem Cell Transplantation.

Donor Lymphocyte Infusion for Relapsed Hematological Malignancies After Allogeneic Hematopoietic Cell Transplantation: Prognostic Relevance of the Initial CD3+ T Cell Dose

Improved Stem Cell Transplant Related Mortality for AL Amyloidosis At a Single Transplant Center

Prospective Phase II Multicenter Study of Conditioning with Treosulfan, Fludarabine and Low-Dose (2 Gy) Total Body Irradiation Followed by Hematopoietic Cell Transplantation From Related or Unrelated Donors for Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome

Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes At US Transplant Centers: A Center for International Blood and Marrow Transplant Research (CIBMTR) Study

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Second Allogeneic Hematopoietic Cell Transplantation in Patients with Hematologic Malignancies for Relapse After First Allografts

Calculated NIH Response Correlates with Changes in Patient-Reported Symptoms but Not with Quality of Life: Results From the Chronic Gvhd Consortium

Interaction of Age and Comorbidities and Their Impacts on Hematopoietic Cell Transplantation (HCT) Outcomes

Impact of Comorbidities on Early and Late Mortalities After Allogeneic Hematopoietic Cell Transplantation (HCT)

Incidence, Risk Factors and Outcomes of Sclerotic Chronic Graft-Versus-Host Disease (GVHD) Phenotype After Allogeneic Hematopoietic Cell Transplantation

Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) or Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm,

Peripheral Blood Stem Cell Mobilization with Single Agent Plerixafor Induces FoxP3 Expression in Donor T Cells and Enables Durable Long Term Hematopoietic Engraftment Across Mismatched Major Histocompatibility Complex Barriers

Comparison of Proposed NIH Response Criteria with Clinician-Reported Changes in Organ-Specific and Overall Response

Transplantation of Peripheral Blood Cells As Compared with Bone Marrow From HLA-Identical Related Donors Is Associated with Superior Long-Term Outcomes

Multi-Institutional Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index (HCT-CI) for HCT Outcomes

Impacts of Cytogenetic Abnormalities and Prior Alemtuzumab on Outcomes of Patients (pts) with High-Risk Chronic Lymphocytic Leukemia (CLL) Given Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT)

Sequential Autologous Followed by Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation (HCT) From HLA-Matched Related or Unrelated Donors Improves Outcomes of Patients (pts) with Bulky Lymphoma or Chronic Lymphocytic Leukemia (CLL)

Chronic Gvhd Global Severity According to NIH Consensus Criteria: Results From the Chronic Gvhd Consortium

Treatment of Recurrent or Persistent AML/MDS After Allogeneic Hematopoietic Cell Transplantation with Azacitidine.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only